 | |
| Company type | Aktiengesellschaft |
|---|---|
| WBAG: ICLL OTCQX: INRLY | |
| Industry | Biotechnology |
| Founded | 1998 |
| Defunct | 2013 |
| Fate | Merged with Vivalis SA |
| Successor | Valneva SE |
| Headquarters | , |
Key people | Thomas Lingelbach (CEO), Michel Gréco (Chairman of the supervisory board) |
| Products | Development of vaccines |
| Revenue | €34.2 million (2010)[1] |
 (€251.2 million) (2010)[1] | |
| (€255.2 million) (2010)[1] | |
| Total assets | €225.2 million (end 2010)[1] |
| Total equity | €121.1 million (end 2010)[1] |
Number of employees | 410 (average, 2010)[1] |
| Website | www |
Intercell AG was a biotechnology company based in Vienna which focused on the development of modern prophylactic and therapeutic vaccines against infectious diseases. The company merged with Vivalis to form Valneva SE in 2012.[2] Intercell was formed in 1998 as a spin-off of the Research Institute of Molecular Pathology (IMP) in Vienna.[3] It employs 400 people in Austria, Scotland and the United States.
- ^ a b c d e f "Annual Report 2010" (PDF). Intercell. Archived from the original (PDF) on 26 June 2011. Retrieved 3 May 2011.
- ^ Carroll, John (17 December 2012). "Troubled Intercell throws in the towel, signs off on merger deal with Vivalis". Fierce Biotech. Retrieved 27 January 2018.
- ^ "Research Institute of Molecular Pathology (IMP) - About the IMP > History". Research Institute of Molecular Pathology. Retrieved 2009-07-25. [dead link]